LexaGene Announces Collaboration with Texas A&M Veterinary Medical Diagnostics Laboratory

LexaGene Holdings Inc a biotechnology company that develops instrumentation for pathogen detection, announced today that it has entered into a collaborative agreement with Texas A&M Veterinary Medical Diagnostics Laboratory.

Under this agreement , Texas A&M will provide canine urine samples to LexaGene for testing on the Company’s LX6 prototype for more effective pathogen detection. Prior to sending the samples to LexaGene, Texas A&M will characterize them using conventional diagnostic technologies.“

We are happy to add Texas A&M to our growing list of collaborators that are sending us samples , as this allows us to continue to refine our assays and optimize the LX6 prototype. It is important for us to work with collaborators in different geographic regions to get adequate representation of diseases that thrive in different climates,” said Dr. Jack Regan, LexaGene’s CEO.

He continues, “For example, Rickettsia (Rocky Mountain spotted fever) is a tick-borne infection that commonly affects dogs in the Mid-West and Southern states, but is found less often in the Northern states. Conversely, Borrelia burgdorferi and Anaplasma phagocytophilum are common dog pathogens in the Northeast, but are rarely found in the South.

For this reason, we need to have collaborators in all corners of the United States to ensure the LX6 is equally effective in each state .”

Company: LexaGene


LexaGene is a biotechnology company developing a fully automated pathogen detection platform for use at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. LexaGene’s technology aims to transform the way organizations prevent and diagnose disease in multi-billion dollar markets such as food safety, veterinary diagnostics, water quality monitoring, aquaculture pathogen surveillance, and more.

LexaGene’s patented microfluidic system was invented by company founder and CEO, Dr. Jack Regan, who was a lead scientist in developing a predecessor instrument designed for bio-warfare surveillance that was adopted by the Department of Homeland Security for the BioWatch Program and a second R&D instrument that was designed for detecting respiratory pathogens from nasal swab samples. The development of these instruments was supported by $20M in government funding.

LexaGene’s experienced leadership team is driving company growth with a focus on innovation, pursuing unique market opportunities, and providing shareholder value.

Send Enquiry for this story

By selecting this checkbox you are giving a consent to HHMGlobal.com to store your submitted information.
See our Privacy Policy to learn more about how we use data.